Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Pergolide Versus Bromocriptine for Levodopa-induced Complications in Parkinson's Disease: Cochrane Systematic Review." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437448/0/images/ios-appstore-badge.png. Accessed 04 May 2024.
Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437448/0/images/ios-appstore-badge.png. Accessed May 4, 2024.
Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/437448/0/images/ios-appstore-badge.png
Pergolide Versus Bromocriptine for Levodopa-induced Complications in Parkinson's Disease: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. [cited 2024 May 04]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437448/0/images/ios-appstore-badge.png.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
ID - 437448
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437448/0/images/ios-appstore-badge.png
DB - Evidence Central
DP - Unbound Medicine
ER -